Karyopharm Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Feb '26 Feb 25, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Capitalization	187	135	85	99	385	486
Market Cap Growth	136.31%	57.91%	-13.86%	-74.26%	-20.76%	-57.36%
Enterprise Value	428	359	220	201	549	595
Last Close Price	10.07	7.36	10.14	12.97	51.00	96.45
PS Ratio	1.27	0.92	0.59	0.68	2.45	2.32
PB Ratio	-	-0.46	-0.46	-0.73	-23.11	-6.10
EV/Sales Ratio	2.93	2.46	1.51	1.38	3.50	2.84
Debt / Equity Ratio	-1.04	-1.04	-1.44	-2.27	-18.72	-3.94
Net Debt / Equity Ratio	-0.83	-0.83	-0.86	-0.87	-2.03	-1.07
Net Debt / EBITDA Ratio	-2.68	-2.68	-1.34	-0.91	-0.24	-0.87
Net Debt / FCF Ratio	-3.21	-3.21	-1.25	-1.27	-0.23	-0.79
Asset Turnover	1.07	1.07	0.72	0.49	0.47	0.68
Inventory Turnover	29.98	29.98	38.35	39.55	36.95	1.01
Quick Ratio	0.98	0.98	1.51	3.16	5.05	3.43
Current Ratio	1.12	1.12	1.70	3.37	5.31	3.74
Return on Assets (ROA)	-41.56%	-41.56%	-36.88%	-27.05%	-26.79%	-19.86%
Return on Capital Employed (ROCE)	-554.60%	-554.60%	-165.50%	-75.80%	-48.70%	-42.40%
Earnings Yield	-105.39%	-145.47%	-89.55%	-144.44%	-42.94%	-25.55%
FCF Yield	-40.52%	-55.93%	-149.55%	-93.59%	-38.88%	-22.09%
Buyback Yield / Dilution	-29.33%	-29.33%	-11.02%	-39.54%	-8.85%	-4.41%

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q